Autolus: The Commercial Engine Is Humming, but the MS Clock Just Moved to October 2027
Q3 revenue rose 95% and guidance was raised again — yet the stock is 48% below its August peak because the BOBCAT readout slipped and Q4 sales are guided flat.
AUTL · Earnings Call · 2026-11-10
Autolus: The Commercial Engine Is Humming, but the MS Clock Just Moved to October 2027
A beat-and-raise that still left the growth question open
Autolus reported $41.2M of AUCATZYL net sales in Q3 2026, up 95% year over year, and $113.1M for the first nine months, up 122%. Management raised full-year guidance to "at or above $150 million" from a prior $140–150M range. On the surface, that is a clean beat-and-raise. But the implied Q4 number — at least $36.9M — is below Q2's $46M and roughly flat with Q3. The first analyst question was blunt about AUCATZYL sales: when do they return to growth? CEO Christian Itin leaned on seasonality and the shape of adoption curves: “when you look at last year's trajectory, you could see that in last year's trajectory, you had basically Q2, Q3, Q4 in similar levels of sales that we had throughout the year.” — Christian Itin, Chief Executive Officer · 2026-11-10 He added that the year-three and year-four slope of a product launch is typically smaller than year one to year two, and pointed to ASH and real-world ROCCA data as the next catalysts for 2027. This is not a new debate. On the August call, Salim Syed of Mizuho asked whether the high end of guidance implied a decline versus Q2's $45M. “when you look at the high end of the guide, it would imply a slight decline versus the 2Q $45 million revenue,” — Salim Syed, Analyst · 2026-08-11 he said. The CEO's answer then was that seasonality and prudence were baked in. The difference now is that guidance has been raised and the Q4 implication is still flat — so the bar for 2027 has moved up without a visible reacceleration in the fourth quarter. That is the commercial tension in the print.The quiet win is gross margin
The operational story is stronger than the top-line cadence. Gross margin reached 57% in Q3, up from 55% in Q2 and a negative margin a year ago; year-to-date it is 44%. Cost of sales fell to $17.9M from $28.6M a year earlier. Management says it will manufacture more than double the number of products in 2026 versus 2025 with a staffing level below last year's — a real efficiency gain at the manufacturing facility. The company still targets a 65–70% peak gross margin for the mature ALL business, and now says it expects to approach the upper end of that range in 2028. That matters because the market is no longer paying for the story on revenue alone. Price-to-revenue was 1.2x in the latest fundamentals, down 82% year over year and from 45.9x in mid-2024. With a $351M market cap, the equity is now priced more like a commercial specialty-pharma launch than a platform option. Total revenue was $46M in Q2 2026, up 118% year over year, before dipping to $41.2M in Q3. Free cash flow was -$26M in Q2, an improvement from -$80M a year earlier. The gross-margin line is the proof point that the launch can eventually carry the P&L; the revenue line is not yet accelerating enough to make that case on its own. Center onboarding is the other underappreciated positive. Autolus had 90 U.S. centers authorized at quarter-end and 18 in the U.K., ahead of its 80-center U.S. target. Management estimates that roughly 80 U.S. centers cover about 80% of the patient opportunity. The next phase is more granular: center onboarding is becoming new center targeting, driven by younger physicians moving from academic settings into community centers. Itin described it as “very targeted and it's community-driven.” — Christian Itin, Chief Executive Officer · 2026-11-10 That is a more surgical commercial model than simply adding logos — and it explains why the company is at 90 centers rather than the 80 it originally planned. The positive experience of treating physicians remains the adoption engine, as it has been all year.Progressive MS: the catalyst moved, and that is the story
The real change in this report is not revenue or margin. It is the timing of the BOBCAT progressive MS data. Autolus said it will present first data at ECTRIMS in October 2027, not at ACTRIMS in March 2027. The rationale is KOL feedback that EDSS stabilization needs at least 12 months of follow-up, with 24 months preferable, to distinguish true disease arrest from noise. “KOLs at the recent ACTRIMS-ECTRIMS 2026 meeting in October were very clear that EDSS stabilization with less than 12 months of follow-up has limited correlation with true disease arrest or even reversal.” — Christian Itin, Chief Executive Officer · 2026-11-10 By October 2027, the company expects 12 patients with at least 12 months of follow-up and 12 more with six to 12 months. That is a defensible scientific choice. It is also a seven-month delay in the company's most important binary catalyst, and it lands on a stock already down 48% from its August peak and 18% over the last 90 days. The contrast with the broader tape is stark: the global 90-day advancers include B cell malignancy names such as ABBV, GMAB and ONC, up 45% on average, while AUTL has de-rated. The sector is not short of enthusiasm for B-cell and CAR-T biology; it is short of patience for a company-specific readout that keeps moving. Management insists the study itself is on track. The distinction between trial conduct and data disclosure matters to investors. Prior calls framed the MS data as a 2026–2027 event. In May, Itin said “as we look into next year, I think we start to have more data points that look at the actual disease scores.” — Christian Itin, Chief Executive Officer · 2026-05-14 Now the first integrated view is October 2027. The goalposts have not moved dramatically, but they have moved enough to remove a near-term catalyst.The company is also adding a second preconditioning regimen to BOBCAT — Flu/Cy conditioning versus bendamustine — and expanded the study from 18 to 24 patients. Bendamustine is less hematotoxic but also less potent as a conditioning agent in leukemia and lymphoma; the trade-off is central to the autoimmune benefit-risk case. That is a genuine scientific nuance, but it also means more variables before a clean readout.we're going into the fall meeting because, frankly, the data at the March meeting, we stated that would not have been actionable from a development perspective or development decision perspective.